Karyopharm Therapeutics Gets $20.5 Million
5/14/2013 8:30:32 AM
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
Clinical-stage biopharma Karyopharm Therapeutics has secured $20.5 million of a $60 million offering. It’s the second round of funding received by the Natick, Mass. developer of cancer- and inflammation-targeting drug candidates. Karyopharm raised the $20 million first tranche of its Series A financing in November of 2010. In addition to CEO and Director Michael Kauffman and Chief Scientific Officer Sharon Shachman, listed on the most recent filing as directors are Alan Barber, acting CFO; Mansoor Mirza, Chief Oncologist at the Copenhagen University Hospital; Barry Greene, president and COO at Alnylam Pharmaceuticals; and Kenneth Weg, co-founder and chairman of the board of directors of Metamark Genetics.
Help employers find you! Check out all the jobs and post your resume.